Lisata Therapeutics, Inc. (LSTA)
Automate Your Wheel Strategy on LSTA
With Tiblio's Option Bot, you can configure your own wheel strategy including LSTA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LSTA
- Rev/Share 0.1163
- Book/Share 2.9182
- PB 0.8854
- Debt/Equity 0.0
- CurrentRatio 7.5169
- ROIC -0.5981
- MktCap 22441302.0
- FreeCF/Share -2.0645
- PFCF -1.2637
- PE -1.1628
- Debt/Assets 0.0
- DivYield 0
- ROE -0.6088
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Lisata Therapeutics reports encouraging data from ASCEND Cohort B evaluating certepetide in pancreatic cancer
Published: June 26, 2025 by: Proactive Investors
Sentiment: Positive
Lisata Therapeutics Inc (NASDAQ:LSTA), in collaboration with the Australasian Gastro-Intestinal Trials Group and the NHMRC Clinical Trials Centre at the University of Sydney, announced positive preliminary results from Cohort B of the ASCEND Phase 2b clinical trial evaluating certepetide in combination with standard-of-care chemotherapy in metastatic pancreatic ductal adenocarcinoma (mPDAC). The ASCEND trial is a 158-patient, double-blind, randomized, placebo-controlled study assessing the addition of certepetide to standard-of-care gemcitabine and nab-paclitaxel.
Read More
Lisata Therapeutics to lead development of OUD therapy under expanded alliance with GATC Health
Published: June 17, 2025 by: Proactive Investors
Sentiment: Positive
Lisata Therapeutics Inc (NASDAQ:LSTA) and GATC Health have expanded their strategic alliance aimed at accelerating and improving the success rate of drug development using artificial intelligence (AI). The expanded collaboration builds on prior work in which GATC provided AI-based analysis supporting Lisata's certepetide drug candidate.
Read More
Lisata Therapeutics, Inc. (LSTA) Q1 2025 Earnings Conference Call Transcript
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Lisata Therapeutics, Inc. (NASDAQ:LSTA ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants John Menditto - VP of IR and Corporate Communications David Mazzo - President and CEO James Nisco - SVP of Finance and Treasury and Chief Accounting Officer Kristen Buck - EVP of R&D and Chief Medical Officer Conference Call Participants Kemp Dolliver - Brookline Capital Market Pete Enderlin - MAZ Partners Operator Welcome to the Lisata Therapeutics First Quarter 2025 Financial Results and Business Update Conference Call. Currently, all participants are in listen-only mode.
Read More
Lisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
BASKING RIDGE, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for the three months ended March 31, 2025, on Thursday, May 8, 2025, after the close of trading and will host a conference call at 4:30 p.m.
Read More
Lisata Therapeutics signs research license with Catalent
Published: April 15, 2025 by: Proactive Investors
Sentiment: Positive
Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has entered into a research license agreement with Catalent to evaluate certepetide, its iRGD cyclic peptide candidate, using Catalent's SMARTag antibody-drug conjugate (ADC) platform. The research will focus on preclinical testing for diseases such as advanced solid tumors.
Read More
Lisata Therapeutics partners with GATC Health to advance AI-driven drug development
Published: March 05, 2025 by: Proactive Investors
Sentiment: Positive
Lisata Therapeutics Inc (NASDAQ:LSTA) has announced the first step of an intended multi-part strategic agreement with GATC Health, a leading drug discovery firm leveraging artificial intelligence. The partnership combines GATC's proprietary Multiomics Advanced Technology (MAT) AI platform with Lisata's expertise in drug development to reduce risks and improve efficiency in bringing new therapies to market.
Read More
Lisata Therapeutics, Inc. (LSTA) Q4 2024 Earnings Call Transcript
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Lisata Therapeutics, Inc. (NASDAQ:LSTA ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants John Menditto - Vice President of Investor Relations and Corporate Communications David Mazzo - President and Chief Executive Officer Kristen Buck - Executive Vice President of R&D and Chief Medical Officer James Nisco - Senior Vice President of Finance and Treasury and Chief Accounting Officer Conference Call Participants Sara Nik - H.C. Wainwright Peter Enderlin - MAZ Partners Steve Brozak - WBB Securities, LLC Kemp Dolliver - Brookline Capital Markets Operator Welcome to the Lisata Therapeutics' Full Year 2024 Financial Results and …
Read More
Lisata Therapeutics CEO: 2025 to be ‘data-rich' as certepetide trials progress
Published: February 27, 2025 by: Proactive Investors
Sentiment: Positive
Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazza told investors that he expects 2025 to be a “data-rich year” in a statement accompanying its full-year 2024 financial results. The pharmaceutical company highlighted progress in its clinical pipeline, including encouraging preliminary data from a Phase 2b pancreatic cancer trial.
Read More
Lisata Therapeutics to Report Full Year 2024 Financial Results and Provide a Business Update on Thursday, February 27, 2025
Published: February 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
BASKING RIDGE, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for the twelve months ended December 31, 2024, on Thursday, February 27, 2025, after the close of trading and will host a conference call at 4:30 p.m. Eastern time.
Read More
About Lisata Therapeutics, Inc. (LSTA)
- IPO Date 1999-03-01
- Website https://www.lisata.com
- Industry Biotechnology
- CEO David J. Mazzo
- Employees 26